CHIR98014 – 5 mg

Brand:
Cayman
CAS:
556813-39-9
Storage:
-20
UN-No:
Non-Hazardous - 2811 / 6.1

The two isoforms of glycogen synthase kinase 3, GSK3α and GSK3β, constitutively phosphorylates and inactivates glycogen synthase, preventing glycogen synthesis.{19045} They also phosphorylate proteins that are relevant to Alzheimer’s disease and osteogenesis.{25567,25565,25566} CHIR98014 is a reversible, cell-permeable inhibitor of GSK3α and GSK3β (IC50 = 0.65 and 0.58 nM, respectively).{19045} It is inactive against a series of other serine/threonine or tyrosine kinases.{19045} Through its effects on GSK3, CHIR98014 stimulates glycogen synthase in cells (EC50 = 106 nM), potentiates insulin-dependent glucose transport in isolated muscle strips, and improves glucose disposal in diabetic animals.{19045} CHIR98014 also reduces tau phosphorylation in rat brains and supports Wnt signaling during osteogenesis.{22495,25566}  

 

SKU: - Category:

Description

A reversible, cell-permeable inhibitor of GSK3α and GSK3β (IC50 = 0.65 and 0.58 nM, respectively); stimulates glycogen synthase in cells (EC50 = 106 nM), potentiates insulin-dependent glucose transport in isolated muscle strips, and improves glucose disposal in diabetic animals


Formal name: N6-[2-[[4-(2,4-dichlorophenyl)-5-(1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]-3-nitro-2,6-pyridinediamine

Synonyms: 

Molecular weight: 486.3

CAS: 556813-39-9

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|GSK3||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Endocrinology & Metabolism|Bone Growth & Remodeling||Research Area|Endocrinology & Metabolism|Carbohydrate Metabolism||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Neuroscience|Neurodegenerative Disorders|Alzheimer’s Disease